EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer

Yueting Huang, Yang Yang, Yanni Xie iD, Yue Shu, Siqi Yang, Xuezhi Long, Zhipeng Wen, Xiaolu Duan iD, Li Fu, Di Gu, Tuxiong Huang

Drug Design, Development and Therapy · 2026

DOI: 10.2147/dddt.s576346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Yueting Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Urological Diseases, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Gua…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Immunotherapy, HLA-A2 Antigen, Glutamate Carboxypeptidase II. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsImmunotherapyHLA-A2 AntigenGlutamate Carboxypeptidase IIOxidoreductasesPeptidesAntigens, SurfaceMaleAnimalsHumansMiceMice, TransgenicT-Lymphocytes, CytotoxicMolecular Docking SimulationAntigens, Neoplasm

Stichwörter der Autor:innen

HLA-A*02:01cytotoxic T lymphocyteepitopepeptide-based immunotherapyprostate cancer

Substanzen

HLA-A2 AntigenHLA-A*02:01 antigenGlutamate Carboxypeptidase IISTEAP1 protein, humanOxidoreductasesPeptidesAntigens, SurfaceFOLH1 protein, humanAntigens, Neoplasm

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Urological Diseases, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
  • Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pharmacology and International Cancer Center, Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China.

ORCID-Profile: Yanni Xie, Xiaolu Duan

Zitieren

APA

Huang, Y., Yang, Y., Xie, Y., Shu, Y., Yang, S., Long, X., Wen, Z., Duan, X., Fu, L., Gu, D., & Huang, T. (2026). Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s576346

Vancouver

Huang Y, Yang Y, Xie Y, Shu Y, Yang S, Long X, et al. Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s576346

BibTeX
@article{Huang2026,
  author = {Huang, Yueting and Yang, Yang and Xie, Yanni and Shu, Yue and Yang, Siqi and Long, Xuezhi and Wen, Zhipeng and Duan, Xiaolu and Fu, Li and Gu, Di and Huang, Tuxiong},
  title = {Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  doi = {10.2147/dddt.s576346}
}
Kostenlos starten →